CNTB: Rademikibart reduced treatment failure by 66% and improved lung function in acute asthma exacerbations
A Phase 2 study showed rademikibart as an add-on for acute asthma exacerbations reduced treatment failure by 66% and improved lung function significantly at Day 7, with a favorable safety profile. Plans are underway for Phase 3 development and COPD data is expected soon.Original document: Connect B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.